The present study aimed to evaluate the anti-
tumor efficacy of the
epidermal growth factor receptor (EGFR)-targeting
recombinant fusion protein Fv-LDP-D3 and its
antibody-drug conjugate Fv-LDP-D3-AE against
esophageal cancer. Fv-LDP-D3, consisting of the fragment variable (Fv) of an anti-EGFR antibody, the
apoprotein of
lidamycin (LDP), and the third domain of
human serum albumin (D3), exhibited a high binding affinity for EGFR-overexpressing
esophageal cancer cells, inhibited EGFR phosphorylation and down-regulated
inosine monophosphate dehydrogenase type II (IMPDH2) expression. Fv-LDP-D3 was taken up by
cancer cells through intensive macropinocytosis; it inhibited the proliferation and induced the apoptosis of
esophageal cancer cells. In vivo imaging revealed that Fv-LDP-D3 displayed specific
tumor-site accumulation and a long-lasting retention over a 26-day period. Furthermore, Fv-LDP-D3-AE, a pertinent
antibody-drug conjugate prepared by integrating the enediyne chromophore of
lidamycin into the Fv-LDP-D3 molecule, displayed highly potent cytotoxicity, inhibited migration and invasion, induced apoptosis and DNA damage, arrested cells at G2/M phase, and caused mitochondrial damage in
esophageal cancer cells. More importantly, both of Fv-LDP-D3 and Fv-LDP-D3-AE markedly inhibited the growth of
esophageal cancer xenografts in athymic mice at well tolerated doses. The present results indicate that Fv-LDP-D3, and Fv-LDP-D3-AE exert prominent antitumor efficacy associated with targeting EGFR, suggesting their potential as promising candidates for targeted
therapy against
esophageal cancer.